Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
The New York Stock Exchange (NYSE) has commenced proceedings to delist Elme Communities' common shares and immediately suspended trading due to abnormally low selling price levels. The company does not intend to appeal the decision as it is already executing a previously approved Plan of Sale and Liquidation. Elme anticipates its shares will begin trading over-the-counter (OTC) under the symbol 'ELMES' on October 26, 2026.
Phathom Pharmaceuticals announced that the FDA has opened a public docket to solicit comments regarding legal challenges brought by BDR Pharmaceuticals against the FDA's decision to grant VOQUEZNA 10 years of New Chemical Entity (NCE) exclusivity. The litigation challenges the exclusivity period that currently protects VOQUEZNA through May 2032, and a second potential generic filer, Saba Ilac Sanayii Ve Ticaret AS, has also indicated intent to join the legal challenge.
ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted antibody-drug conjugate ARR-217 in patients with gastrointestinal cancers, reporting a 44.8% objective response rate at the 6mg/kg dose in late-line colorectal cancer patients. The study, conducted in partnership with Lepu Biopharma, showed a manageable safety profile and has advanced into Phase 1b dose optimization with further data expected in 2027.
Counterparty
Lepu Biopharma Co., Ltd.
“These initial results reinforce our confidence in ARR-217 and in CDH17 as a potential therapeutic target for patients with gastrointestinal cancers who face limited treatment options following prior lines of therapy.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
“We believe the responses observed in this heavily pretreated patient population, together with a manageable safety profile, provided a strong foundation for advancing ARR-217 into a Phase 1b dose optimization study.”
Bing Yao, Ph.D., Chief Executive Officer of ArriVent
Eikon Therapeutics presented updated Phase 1b data from its TeLuRide-005 trial evaluating EIK1001 in combination with pembrolizumab and chemotherapy for advanced NSCLC at the 2026 ESMO Congress. The trial demonstrated a 63.1% objective response rate (ORR) and 89.2% disease control rate (DCR) across the pooled population, with a safety profile supportive of outpatient administration. The squamous cohort specifically showed a 72.4% ORR and 100% DCR with a median duration of response of 12.9 months.
Cyber Enviro-Tech, Inc. entered into Amendment No. 2 to its existing Equity Purchase Agreement with Monroe Street Capital Partners, LP, which allows the company to sell up to $30 million of common stock. The amendment modifies the pricing mechanism for 'put notices' to be based on the end-of-day volume-weighted average price (EOD VWAP) rather than the lowest traded price, while maintaining a 15% discount factor. The company also disclosed a prior amendment that reduced the minimum put amount to facilitate easier access to the capital facility.
Charlton Aria Acquisition Corp notified Nasdaq that it failed to satisfy audit committee independence requirements due to a compensatory payment made to a firm associated with director Kyoung Tak Kim. The company regained compliance on October 22, 2026, by removing Mr. Kim from the audit committee and appointing Wang Jo Cha as his replacement.
Idaho Copper Corporation announced the filing of its Preliminary Economic Assessment (PEA) and NI 43-101 Technical Report on the Canadian SEDAR+ system. The company also indicated it intends to file a US-compliant version of the PEA (Subpart 1300 of Regulation S-K) in the near future.
Ladder Capital Corp reported its third-quarter 2026 results, identifying as a large accelerated filer with 125,992,003 shares of Class A common stock outstanding as of October 16, 2026. The filing highlights significant macroeconomic and geopolitical risks, including global trade tensions, armed conflicts in the Middle East and Ukraine, and potential impacts from AI-enabled cybersecurity threats.
Bluerock Private Real Estate Fund President Jordan B. Ruddy Buys $25K of Stock
Jordan B. Ruddy, President, bought 2,040 shares of Bluerock Private Real Estate Fund at $12.25 a share, worth $25K in total on Oct 21, 2026. Shares held after the trade: 19,232 (+11.9%).
Natera Director Jonathan Sheena Sells $1.29M of Stock
Jonathan Sheena, Director, sold 3,150 shares of Natera, Inc. at $406.50 to $416.67 a share (average $410.55) in 8 transactions, worth $1.29M in total on Oct 21, 2026. Shares held after the trade: 218,164 (-0.1%).
CrowdStrike Holdings President and CEO George Kurtz Sells $4.76M of Stock
George Kurtz, President and CEO, sold 20,000 shares of CrowdStrike Holdings, Inc. at $229.25 to $245.34 a share (average $238.09) in 23 transactions, worth $4.76M in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 7,401,504 (-0.0%).
Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $10.3M of Stock
Qiming Corporate GP VI Ltd., 10% Owner, sold 342,527 shares of Alamar Biosciences, Inc. at $29.00 to $30.81 a share (average $29.92) in 23 transactions, worth $10.3M in total between Oct 21, 2026 and Oct 22, 2026. Shares held after the trade: 1,789,183 (-0.1%).
Vinci Compass Investments Head of Global IP&S Fernando Lovisotto Sells $369K of Stock
Fernando Lovisotto, Head of Global IP&S, sold 33,110 shares of Vinci Compass Investments Ltd. at $10.95 to $11.42 a share (average $11.13) in 4 transactions, worth $369K in total between Oct 19, 2026 and Oct 22, 2026. Shares held after the trade: 889,406 (-0.6%).
Vinci Compass Investments Pres. of Finance & Operations Bruno Augusto Sacchi Zaremba Sells $480K of Stock
Bruno Augusto Sacchi Zaremba, Pres. of Finance & Operations, sold 43,075 shares of Vinci Compass Investments Ltd. at $10.96 to $11.42 a share (average $11.15) in 4 transactions, worth $480K in total between Oct 19, 2026 and Oct 22, 2026. Shares held after the trade: 935,257 (-0.8%).
Zoom Communications Insider Santiago Subotovsky Sells $427K of Stock
Santiago Subotovsky sold 4,258 shares of Zoom Communications, Inc. at $96.61 to $101.19 a share (average $100.21) in 4 transactions, worth $427K in total between Oct 15, 2026 and Oct 21, 2026. Shares held after the trade: 117,974 (-0.3%).
Zoom Communications Insider Herbert Raymond McMaster Sells $152K of Stock
Herbert Raymond McMaster sold 1,500 shares of Zoom Communications, Inc. at $101.25 a share, worth $152K in total on Oct 21, 2026. Shares held after the trade: 6,979 (-17.7%).
Zoom Communications CFO Michelle Chang Sells $1.04M of Stock
Michelle Chang, CFO, sold 10,156 shares of Zoom Communications, Inc. at $101.93 a share, worth $1.04M in total on Oct 21, 2026. Shares held after the trade: 30,282 (-25.1%).
Charles River Laboratories International CEVP, Disc & Safety Assessment Shannon M. Parisotto Sells $743K of Stock
Shannon M. Parisotto, CEVP, Disc & Safety Assessment, sold 2,156 shares of Charles River Laboratories International, Inc. at $344.41 a share, worth $743K in total on Oct 21, 2026. Shares held after the trade: 4,807 (-31.0%).
Snowflake Insider Benoit Dageville Sells $16.1M of Stock
Benoit Dageville sold 50,000 shares of Snowflake Inc. at $321.74 a share, worth $16.1M in total on Oct 21, 2026. Shares held after the trade: 2,301,543 (-2.1%).
Pimco New York Municipal Income Fund II Insider Bank of America Corp /De/ Buys $77.1K of Stock
Bank of America Corp /De/ bought 12,170 shares of Pimco New York Municipal Income Fund II at $6.33 a share, worth $77.1K in total on Oct 21, 2026. Shares held after the trade: 12,170.
Olivia Nottebohm, COO, sold 5,293 shares of Box Inc at $41.58 a share, worth $220K in total on Oct 21, 2026. Shares held after the trade: 481,466 (-1.1%).
Greenwave Technology Solutions has scheduled its 2026 Annual Meeting of Stockholders for December 7, 2026, with a record date of October 23, 2026. The company established a deadline of October 28, 2026, for stockholder proposals to be included in the proxy materials and November 2, 2026, for other business to be brought before the meeting.
Innventure, Inc. received a deficiency notice from Nasdaq on October 23, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until April 21, 2027, to regain compliance by maintaining a $1.00 bid price for at least 10 consecutive business days. If compliance is not met, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market.
The Andersons, Inc. announced the termination of Sarah J. Zibbel, Executive Vice President and Chief Human Resources Officer, effective October 31, 2026, due to the elimination of her position in a department restructuring. Ms. Zibbel will receive benefits under the company's severance policy and retain certain restricted stock units and pro-rated performance shares from 2024.
Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.
Silvercrest Asset Management Group 10% Owner Equinox Partners Investment Management LLC Buys $353K of Stock
Equinox Partners Investment Management LLC, 10% Owner, bought 34,126 shares of Silvercrest Asset Management Group Inc. at $10.24 to $10.47 a share (average $10.33) in 4 transactions, worth $353K in total between Oct 15, 2026 and Oct 22, 2026. Shares held after the trade: 833,799 (+0.4%).
Edesa Biotech approved significant annual base salary increases for its top executives, including CEO Dr. Pardeep Nijhawan, President Dr. Michael Brooks, and CFO Peter Weiler. The raises are retroactive to July 1, 2026, and represent the first adjustments to executive base salaries since 2023.
22nd Century Group filed a prospectus supplement to sell up to $18.8 million in common stock through an at-the-market (ATM) offering program. The company disclosed that during October 2026, it sold approximately 15.79 million shares, raising gross proceeds of approximately $4.7 million.
HOOPS SCOUTING USA generated its first revenues of $20,000 in fiscal 2026 but reported a net loss of $71,064 and an accumulated deficit of $382,901. The company received a going concern opinion from its auditors due to insufficient capital reserves and a working capital deficit of $247,851.
Azio AI Holdings $2.3M Debt Financing with Azio Corporation
Azio AI Holdings entered into a $2.3 million unsecured revolving credit facility with Azio Corporation, which includes $2.225 million in prior advances. The facility carries an 8.5% annual interest rate and matures on October 21, 2027. Proceeds will be used for general working capital purposes.